Immune Design Corp.
IMDZ
IMDZ was delisted on the 1st of April, 2019.
80 hedge funds and large institutions have $108M invested in Immune Design Corp. in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 24 increasing their positions, 17 reducing their positions, and 14 closing their positions.
57% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 14
41% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 17
35% more capital invested
Capital invested by funds: $80.3M → $108M (+$28.1M)
11% more funds holding
Funds holding: 72 → 80 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$1.77M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.01M |
| 3 |
BlackRock
New York
|
+$813K |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$386K |
| 5 |
State Street
Boston,
Massachusetts
|
+$292K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$1.83M |
| 2 |
JP Morgan Chase
New York
|
-$1.73M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.49M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$549K |
| 5 |
TI
Telemetry Investments
New York
|
-$539K |
IMDZ Hedge Fund Activity: Q2 2018 in Review
80 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Immune Design Corp. (IMDZ) for Q2 2018, worth a combined $108M — up 35% from $80.3M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new IMDZ positions and 14 closed out — a net gain of 8 holders — while 24 added to existing stakes and 17 trimmed.
The largest buyer was Portolan Capital Management, opening a new position worth an estimated $1.77M. The largest seller was Bain Capital Public Equity Management, cutting an estimated $1.83M.
- 80 institutional investors held Immune Design Corp. (IMDZ) as of Q2 2018, up from 72 in Q1 2018.
- Funds reported $108M of Immune Design Corp. stock for Q2 2018, up 35% quarter-over-quarter.
- 22 funds opened new Immune Design Corp. positions in Q2 2018 and 14 closed out, a net change of +8 holders.
- The largest Immune Design Corp. buyer in Q2 2018 was Portolan Capital Management, an estimated $1.77M added.
- The largest Immune Design Corp. seller in Q2 2018 was Bain Capital Public Equity Management, an estimated $1.83M sold.
Based on aggregated 13F filings for Q2 2018.